Marie Lindgren1, Jan Samuelsson2, Lars Nilsson3, Håvar Knutsen4, Waleed Ghanima5, Johan Westin6, Peter L Johansson7,8, Björn Andréasson7,8. 1. Department of Medicine, Kalmar County Hospital, Kalmar, Sweden. 2. Department of Medicine, Stockholm South Hospital, Stockholm, Sweden. 3. Department of Hematology, Skåne University Hospital, Lund, Sweden. 4. Department of Hematology, Ullevål University Hospital, Oslo, Norway. 5. Department of Medicine, Östfold Hospital, Fredrikstad, Norway. 6. Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, Sweden. 7. Department of Hematology and Coagulation, Sahlgrenska University Hospital, Gothenburg, Sweden. 8. Department of Medicine, Section of Hematology, NU Hospital, Uddevalla, Sweden.
Abstract
OBJECTIVE: In myeloproliferative neoplasms (MPN), interferon-alpha (IFN-α) is an effective treatment with disease-modifying properties but currently with no clear predictors of treatment outcome. Recent genomewide association studies in chronic hepatitis C have found a strong influence of genetic polymorphism near the IL28B (IFNL3) gene in response to IFN-α treatment. In this study, we sought to evaluate the prognostic impact of IL28B rs12979860, rs8099917, and rs12980275 on IFN-α treatment response in myeloproliferative neoplasms. METHOD: We retrospectively evaluated 100 patients with MPN treated with IFN-α. The hematologic treatment response on IFN-α was compared between patients and correlated with host genetic variations in IL28B. The genotypes of IL28B were determined by allelic discrimination assays. RESULTS: The CC genotype of rs12979860 was found significantly associated with hematologic response in polycythemia vera (PV) with a complete response (CR) in 79% (CC) compared to 48% (non-CC), (P = .036). No association between the genotypes and treatment response on hydroxyurea was found. CONCLUSION: These results imply an effect of IL28B genotype on the outcome of IFN-α treatment in MPN.
OBJECTIVE: In myeloproliferative neoplasms (MPN), interferon-alpha (IFN-α) is an effective treatment with disease-modifying properties but currently with no clear predictors of treatment outcome. Recent genomewide association studies in chronic hepatitis C have found a strong influence of genetic polymorphism near the IL28B (IFNL3) gene in response to IFN-α treatment. In this study, we sought to evaluate the prognostic impact of IL28Brs12979860, rs8099917, and rs12980275 on IFN-α treatment response in myeloproliferative neoplasms. METHOD: We retrospectively evaluated 100 patients with MPN treated with IFN-α. The hematologic treatment response on IFN-α was compared between patients and correlated with host genetic variations in IL28B. The genotypes of IL28B were determined by allelic discrimination assays. RESULTS: The CC genotype of rs12979860 was found significantly associated with hematologic response in polycythemia vera (PV) with a complete response (CR) in 79% (CC) compared to 48% (non-CC), (P = .036). No association between the genotypes and treatment response on hydroxyurea was found. CONCLUSION: These results imply an effect of IL28B genotype on the outcome of IFN-α treatment in MPN.
Authors: Jan Philipp Bewersdorf; Smith Giri; Rong Wang; Nikolai Podoltsev; Robert T Williams; Raajit K Rampal; Martin S Tallman; Amer M Zeidan; Maximilian Stahl Journal: Clin Lymphoma Myeloma Leuk Date: 2020-05-28
Authors: Roland Jäger; Heinz Gisslinger; Elisabeth Fuchs; Edith Bogner; Jelena D Milosevic Feenstra; Jakob Weinzierl; Fiorella Schischlik; Bettina Gisslinger; Martin Schalling; Michael Zörer; Kurt Krejcy; Christoph Klade; Robert Kralovics Journal: Blood Date: 2021-01-21 Impact factor: 22.113
Authors: Jan Philipp Bewersdorf; Smith Giri; Rong Wang; Nikolai Podoltsev; Robert T Williams; Martin S Tallman; Raajit K Rampal; Amer M Zeidan; Maximilian Stahl Journal: Leukemia Date: 2020-09-01 Impact factor: 11.528